Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without bevacizumab as adjuvant therapy after curative resection or ablation for high-risk hepatocellular carcinoma
2018-004105-85Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Durvalumab + bevacizumab, Durvalumab monotherapy and Placebo (3 arms). Primary endpoint: Recurrence-free survival. Started May 2019; status: active.
02
Drugs
durvalumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2018-004105-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004105-85.